Access to Pirfenidone Solution for Inhalation (AP01) for Treatment of Progressive, Fibrosing Interstitial Lung Diseases, including Idiopathic Pulmonary Fibrosis

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-515964-30-00

Acronym

AP01-005

Enrollment

Registered

2024-08-26

Start date

2021-07-14

Completion date

2025-08-18

Last updated

2025-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

including but not limited to idiopathic pulmonary fibrosis (IPF), Interstitial Lung Diseases (ILD)

Brief summary

Not applicable

Detailed description

Treatment-emergent adverse events (AEs), Treatment-emergent deaths

Interventions

DRUGPirfenidone Solution for Inhalation

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Not applicable	—

Secondary

Measure	Time frame
Treatment-emergent adverse events (AEs), Treatment-emergent deaths	—

Countries

Czechia, Netherlands, Poland

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026